{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:52:13Z","timestamp":1780649533185,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s11102-022-01206-2","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T20:10:06Z","timestamp":1642018206000},"page":"420-432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6495-2244","authenticated-orcid":false,"given":"Roberto","family":"Salvatori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Maffei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Brue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas Rao","family":"Valluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Wajnrajch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,12]]},"reference":[{"issue":"24","key":"1206_CR1","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1056\/NEJMra062453","volume":"355","author":"S Melmed","year":"2006","unstructured":"Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355(24):2558\u20132573","journal-title":"N Engl J Med"},{"issue":"11","key":"1206_CR2","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.3390\/jcm8111962","volume":"8","author":"A Akirov","year":"2019","unstructured":"Akirov A, Asa SL, Amer L, Shimon I, Ezzat S (2019) The clinicopathological spectrum of acromegaly. J Clin Med 8(11):1962","journal-title":"J Clin Med"},{"issue":"1","key":"1206_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11102-016-0772-8","volume":"20","author":"L Vilar","year":"2017","unstructured":"Vilar L, Vilar CF, Lyra R, Lyra R, Naves LA (2017) Acromegaly: clinical features at diagnosis. Pituitary 20(1):22\u201332","journal-title":"Pituitary"},{"issue":"11","key":"1206_CR4","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1172\/JCI39375","volume":"119","author":"S Melmed","year":"2009","unstructured":"Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119(11):3189\u20133202","journal-title":"J Clin Invest"},{"issue":"5","key":"1206_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1530\/EJE-16-1064","volume":"176","author":"L Maione","year":"2017","unstructured":"Maione L, Brue T, Beckers A, Delemer B, Petrossians P, Borson-Chazot F, Chabre O, Francois P, Bertherat J, Cortet-Rudelli C et al (2017) Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. Eur J Endocrinol 176(5):645\u2013655","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1206_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","volume":"40","author":"MR Gadelha","year":"2019","unstructured":"Gadelha MR, Kasuki L, Lim DST, Fleseriu M (2019) Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev 40(1):268\u2013332","journal-title":"Endocr Rev"},{"issue":"4","key":"1206_CR7","first-page":"dgz096","volume":"105","author":"A Giustina","year":"2019","unstructured":"Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, Bolanowski M, Bonert V, Bronstein MD, Casanueva FF et al (2019) A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab 105(4):dgz096","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1206_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","volume":"24","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, Molitch ME, Samson SL, Strasburger CJ, van der Lely AJ et al (2021) A Pituitary Society update to acromegaly management guidelines. Pituitary 24(1):1\u201313","journal-title":"Pituitary"},{"issue":"3","key":"1206_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1530\/EJE-15-1042","volume":"174","author":"CJ Strasburger","year":"2016","unstructured":"Strasburger CJ, Karavitaki N, Stormann S, Trainer PJ, Kreitschmann-Andermahr I, Droste M, Korbonits M, Feldmann B, Zopf K, Sanderson VF et al (2016) Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. Eur J Endocrinol 174(3):355\u2013362","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1206_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12902-020-00595-4","volume":"20","author":"EB Geer","year":"2020","unstructured":"Geer EB, Sisco J, Adelman DT, Ludlam WH, Haviv A, Liu S, Mathias SD, Gelbaum D, Shi L (2020) Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice. BMC Endocr Disord 20(1):117","journal-title":"BMC Endocr Disord"},{"key":"1206_CR11","doi-asserted-by":"publisher","first-page":"627711","DOI":"10.3389\/fendo.2021.627711","volume":"12","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Molitch M, Dreval A, Biermasz NR, Gordon MB, Crosby RD, Ludlam WH, Haviv A, Gilgun-Sherki Y, Mathias SD (2021) Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands. Front Endocrinol (Lausanne) 12:627711","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"1206_CR12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11102-020-01038-y","volume":"23","author":"M Fleseriu","year":"2020","unstructured":"Fleseriu M, Fogelfeld L, Gordon MB, Sisco J, Crosby RD, Ludlam WH, Haviv A, Mathias SD (2020) An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies. Pituitary 23(4):347\u2013358","journal-title":"Pituitary"},{"issue":"6","key":"1206_CR13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1530\/EJE-18-0616","volume":"179","author":"M Buchfelder","year":"2018","unstructured":"Buchfelder M, van der Lely AJ, Biller BMK, Webb SM, Brue T, Strasburger CJ, Ghigo E, Camacho-Hubner C, Pan K, Lavenberg J et al (2018) Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. Eur J Endocrinol 179(6):419\u2013427","journal-title":"Eur J Endocrinol"},{"key":"1206_CR14","doi-asserted-by":"crossref","unstructured":"Hayes LD, Sculthorpe N, Herbert P, Baker JS, Spagna R, Grace FM (2015) Six weeks of conditioning exercise increases total, but not free testosterone in lifelong sedentary aging men.Aging Male:1\u20136","DOI":"10.3109\/13685538.2015.1046123"},{"key":"1206_CR15","unstructured":"SOMAVERT (pegvisomant (for injection, for subcutaneous use Prescribing Information. Pfizer. New York, NY. 2013)"},{"issue":"9","key":"1206_CR16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, Strasburger CJ, Luger A, Clemmons DR, Giustina A (2018) A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14(9):552\u2013561","journal-title":"Nat Rev Endocrinol"},{"key":"1206_CR17","doi-asserted-by":"crossref","unstructured":"Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, Bolanowski M, Bonert V, Bronstein MD, Casanueva FF et al (2020) A consensus on the diagnosis and treatment of acromegaly comorbidities: an update.J Clin Endocrinol Metab105(4)","DOI":"10.1210\/clinem\/dgz096"},{"issue":"9295","key":"1206_CR18","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","volume":"358","author":"AJ van der Lely","year":"2001","unstructured":"van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML et al (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358(9295):1754\u20131759","journal-title":"Lancet"},{"issue":"16","key":"1206_CR19","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","volume":"342","author":"PJ Trainer","year":"2000","unstructured":"Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML et al (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342(16):1171\u20131177","journal-title":"N Engl J Med"},{"key":"1206_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1477-7525-2-13","volume":"2","author":"X Badia","year":"2004","unstructured":"Badia X, Webb SM, Prieto L, Lara N (2004) Acromegaly Quality of Life Questionnaire (AcroQoL). Health Qual Life Outcomes 2:13","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"1206_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1046\/j.1365-2265.2002.01597.x","volume":"57","author":"SM Webb","year":"2002","unstructured":"Webb SM, Prieto L, Badia X, Albareda M, Catala M, Gaztambide S, Lucas T, Paramo C, Pico A, Lucas A et al (2002) Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol (Oxf) 57(2):251\u2013258","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1206_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1530\/eje.1.02312","volume":"156","author":"I Schreiber","year":"2007","unstructured":"Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ, German Pegvisomant I (2007) Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156(1):75\u201382","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1206_CR23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2265.2009.03773.x","volume":"73","author":"C Sievers","year":"2010","unstructured":"Sievers C, Br\u00fcbach K, Saller B, Schneider HJ, Buchfelder M, Droste M, Mann K, Strasburger CJ, Stalla GK (2010) Change of symptoms and perceived health in acromegalic patients on pegvisomant therapy: a retrospective cohort study within the German Pegvisomant Observational Study (GPOS). Clin Endocrinol (Oxf) 73(1):89\u201394","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"1206_CR24","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s11102-017-0835-5","volume":"20","author":"AJ van der Lely","year":"2017","unstructured":"van der Lely AJ, Gomez R, Pleil A, Badia X, Brue T, Buchfelder M, Burman P, Clemmons D, Ghigo E, Jorgensen JOL et al (2017) Development of ACRODAT((R)), a new software medical device to assess disease activity in patients with acromegaly. Pituitary 20(6):692\u2013701","journal-title":"Pituitary"},{"issue":"7","key":"1206_CR25","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2018-02281","volume":"104","author":"T Feola","year":"2019","unstructured":"Feola T, Cozzolino A, Simonelli I, Sbardella E, Pozza C, Giannetta E, Gianfrilli D, Pasqualetti P, Lenzi A, Isidori AM (2019) Pegvisomant improves glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J Clin Endocrinol Metab 104(7):2892\u20132902","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1206_CR26","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s12020-018-1792-0","volume":"63","author":"T Brue","year":"2019","unstructured":"Brue T, Lindberg A, van der Jan A, Akerblad AC, Koltowska-Haggstrom M, Gomez R, Droste M, Hey-Hadavi J, Strasburger CJ, Camacho-Hubner C (2019) Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy. Endocrine 63(3):563\u2013572","journal-title":"Endocrine"},{"issue":"11","key":"1206_CR27","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.1210\/jc.2004-0669","volume":"89","author":"NR Biermasz","year":"2004","unstructured":"Biermasz NR, van Thiel SW, Pereira AM, Hoftijzer HC, van Hemert AM, Smit JW, Romijn JA, Roelfsema F (2004) Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 89(11):5369\u20135376","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1206_CR28","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1210\/clinem\/dgaa868","volume":"106","author":"LHA Broersen","year":"2021","unstructured":"Broersen LHA, Zamanipoor Najafabadi AH, Pereira AM, Dekkers OM, van Furth WR, Biermasz NR (2021) Improvement in symptoms and health-related quality of life in acromegaly patients: a systematic review and meta-analysis. J Clin Endocrinol Metab 106(2):577\u2013587","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1206_CR29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrendo.2011.39","volume":"7","author":"SM Webb","year":"2011","unstructured":"Webb SM (2011) Pituitary tumors: coping with \u2018cured\u2019 pituitary tumors. Nat Rev Endocrinol 7(5):251\u2013252","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"1206_CR30","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s11102-011-0310-7","volume":"14","author":"A Ben-Shlomo","year":"2011","unstructured":"Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S (2011) Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 14(3):284\u2013294","journal-title":"Pituitary"},{"issue":"6","key":"1206_CR31","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/cen.13331","volume":"86","author":"N Kyriakakis","year":"2017","unstructured":"Kyriakakis N, Lynch J, Gilbey SG, Webb SM, Murray RD (2017) Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: results from a 5-years prospective study. Clin Endocrinol (Oxf) 86(6):806\u2013815","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"1206_CR32","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1210\/jc.2011-1645","volume":"96","author":"J Tiemensma","year":"2011","unstructured":"Tiemensma J, Kaptein AA, Pereira AM, Smit JW, Romijn JA, Biermasz NR (2011) Affected illness perceptions and the association with impaired quality of life in patients with long-term remission of acromegaly. J Clin Endocrinol Metab 96(11):3550\u20133558","journal-title":"J Clin Endocrinol Metab"},{"key":"1206_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fendo.2017.00040","volume":"8","author":"VJ Geraedts","year":"2017","unstructured":"Geraedts VJ, Andela CD, Stalla GK, Pereira AM, van Furth WR, Sievers C, Biermasz NR (2017) Predictors of quality of life in acromegaly: no consensus on biochemical parameters. Front Endocrinol (Lausanne) 8:40","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"1206_CR34","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ghir.2015.06.008","volume":"25","author":"CD Andela","year":"2015","unstructured":"Andela CD, Biermasz NR, Kaptein AA, Pereira AM, Tiemensma J (2015) More concerns and stronger beliefs about the necessity of medication in patients with acromegaly are associated with negative illness perceptions and impairment in quality of life. Growth Horm IGF Res 25(5):219\u2013226","journal-title":"Growth Horm IGF Res"},{"issue":"1","key":"1206_CR35","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11102-016-0761-y","volume":"20","author":"I Crespo","year":"2017","unstructured":"Crespo I, Valassi E, Webb SM (2017) Update on quality of life in patients with acromegaly. Pituitary 20(1):185\u2013188","journal-title":"Pituitary"},{"issue":"6","key":"1206_CR36","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s11102-015-0665-2","volume":"18","author":"K Yoshida","year":"2015","unstructured":"Yoshida K, Fukuoka H, Matsumoto R, Bando H, Suda K, Nishizawa H, Iguchi G, Ogawa W, Webb SM, Takahashi Y (2015) The quality of life in acromegalic patients with biochemical remission by surgery alone is superior to that in those with pharmaceutical therapy without radiotherapy, using the newly developed Japanese version of the AcroQoL. Pituitary 18(6):876\u2013883","journal-title":"Pituitary"},{"issue":"1","key":"1206_CR37","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000375451","volume":"103","author":"SM Webb","year":"2016","unstructured":"Webb SM, Badia X (2016) Quality of life in acromegaly. Neuroendocrinology 103(1):106\u2013111","journal-title":"Neuroendocrinology"},{"issue":"2","key":"1206_CR38","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11102-015-0693-y","volume":"19","author":"PJ Caron","year":"2016","unstructured":"Caron PJ, Bevan JS, Petersenn S, Houchard A, Sert C, Webb SM, Group PI (2016) Effects of lanreotide autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study. Pituitary 19(2):149\u2013157","journal-title":"Pituitary"},{"key":"1206_CR39","doi-asserted-by":"publisher","first-page":"745843","DOI":"10.3389\/fendo.2021.745843","volume":"12","author":"T Brue","year":"2021","unstructured":"Brue T, Chanson P, Rodien P, Delemer B, Drui D, Marie L, Juban L, Salvi L, Henocque R, Raverot G (2021) Cost-Utility of Acromegaly Pharmacological Treatments in a French Context. Front Endocrinol (Lausanne) 12:745843","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1206_CR40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/BF03346555","volume":"33","author":"C Sardella","year":"2010","unstructured":"Sardella C, Lombardi M, Rossi G, Cosci C, Brogioni S, Scattina I, Webb SM, Gasperi M, Martino E, Bogazzi F (2010) Short- and long-term changes of quality of life in patients with acromegaly: results from a prospective study. J Endocrinol Invest 33(1):20\u201325","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"1206_CR41","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1530\/eje.1.02214","volume":"155","author":"SM Webb","year":"2006","unstructured":"Webb SM, Badia X, Surinach NL, Spanish AcroQol Study G (2006) Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. Eur J Endocrinol 155(2):269\u2013277","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1206_CR42","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/13696998.2017.1419960","volume":"21","author":"X Badia","year":"2018","unstructured":"Badia X, Trainer P, Biermasz NR, Tiemensma J, Carreno A, Roset M, Forsythe A, Webb SM (2018) Mapping AcroQoL scores to EQ-5D to obtain utility values for patients with acromegaly. J Med Econ 21(4):382\u2013389","journal-title":"J Med Econ"},{"issue":"6","key":"1206_CR43","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1530\/EJE-18-0925","volume":"180","author":"J Sibeoni","year":"2019","unstructured":"Sibeoni J, Manolios E, Verneuil L, Chanson P, Revah-Levy A (2019) Patients\u2019 perspectives on acromegaly diagnostic delay: a qualitative study. Eur J Endocrinol 180(6):339\u2013352","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1206_CR44","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s11102-019-00986-4","volume":"22","author":"M Fleseriu","year":"2019","unstructured":"Fleseriu M, Fogelfeld L, Gordon MB, Sisco J, Colwell HH, Ludlam WH, Haviv A, Mathias SD (2019) Development of a novel patient-reported measure for acromegaly: the Acro-TSQ. Pituitary 22(6):581\u2013593","journal-title":"Pituitary"},{"issue":"10","key":"1206_CR45","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1210\/jc.2008-0669","volume":"93","author":"SJ Neggers","year":"2008","unstructured":"Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X, Webb SM, van der Lely AJ (2008) Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 93(10):3853\u20133859","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01206-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-022-01206-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01206-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T19:24:14Z","timestamp":1700076254000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-022-01206-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,12]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1206"],"URL":"https:\/\/doi.org\/10.1007\/s11102-022-01206-2","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,12]]},"assertion":[{"value":"3 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RS is an editor for Pituitary; MF and TB are on the Editorial Board of Pituitary. RS is a principal investigator with research support to Johns Hopkins University for clinical research studies with Crinetics, Novartis, and Chiasma and occasional scientific consultant for Ipsen and Recordati. PM has received honoraria as consultant\/speaker, and is a principal investigator for research grants from CamurusAB, Ipsen, Novartis, Pfizer. SMW has received honoraria as consultant\/speaker or is a principal investigator for research grants from: Pfizer, Novartis, Ipsen, Recordati, HRA, Crinetics and Corcept. TB has received honoraria as consultant\/speaker, or is a principal investigator for research grants from: Pfizer, Novartis Pharma, Ipsen Pharma, Recordati, Merck-Serono, Sandoz, Novo-Nordisk, Advanz Pharma, and Corcept. JL, MPW, SRV, and RG are employees of Pfizer and are stockholders of Pfizer. MF is a principal investigator with research support at Oregon Health & Science University for clinical research studies with Crinetics, Novartis, Recordati, Chiasma, Ionis and occasional scientific consultant for Crinetics, Pfizer, Ipsen, Recordati, and Chiasma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}